[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559151":3},{"organization":4,"armGroups":7,"interventions":45,"overallOfficials":92,"centralContacts":99,"locations":108,"responsibleParty":145,"collaborators":147,"id":151,"slug":152,"hasResults":153,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":158,"sex":159,"minAge":160,"maxAge":51,"enrollmentInfo":161,"targetDuration":51,"studyType":164,"phases":165,"briefSummary":167,"conditions":168,"keywords":51,"overallStatus":110,"whyStopped":51,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},{"fullName":5,"class":6},"H. Lee Moffitt Cancer Center and Research Institute","OTHER",[8,16,22,29,33,39],{"label":9,"type":10,"description":11,"interventionNames":12},"Catchment Area Priority Zone (CAPZ) Intervention - Community Residents and Moffitt Patients","EXPERIMENTAL","Study interventions will be deployed in geographically defined intervention priority zones including Clinical Trial Education sessions and the ACT WONDER²S Phone-line\u002FEmail. Community residents in these zones may be exposed to these interventions.\n\nResidents who are also new patients to Moffitt may be exposed to the CHOICES DA website once they are registered at Moffitt.",[13,14,15],"Behavioral: Clinical Trial Education Sessions (Community Residents Only)","Behavioral: ACT WONDER²S Phone-line\u002FEmail (Community Residents and Moffitt Patients)","Behavioral: New Patient Information (Moffitt Patients Only)",{"label":17,"type":18,"description":19,"interventionNames":20},"Catchment Area Priority Zone (CAPZ) Control - Community Residents and Moffitt Patients","ACTIVE_COMPARATOR","Study interventions will not be deployed in the control priority zones. Community residents in these zones are unlikely to be exposed to any of the study interventions.",[21],"Other: No Intervention",{"label":23,"type":10,"description":24,"interventionNames":25},"Catchment Area Priority Zone (CAPZ) Intervention - Community Physicians","Study interventions will be deployed in geographically defined intervention priority zones including Continuing Medical Education events, the Trial Connect Portal, and Clinical Trial Newsletters. Community physicians in these zones may be exposed to these interventions.",[26,27,28],"Behavioral: Continuing Medical Education Events (CME)","Behavioral: Trial Connect Portal","Behavioral: Clinical Trial Newsletters",{"label":30,"type":18,"description":31,"interventionNames":32},"Catchment Area Priority Zone (CAPZ) Control- Community Physicians","Study interventions will not be deployed in the control priority zones. Community physicians in these zones are unlikely to be exposed to any of the study interventions.",[21],{"label":34,"type":10,"description":35,"interventionNames":36},"Cancer Center Clinical Research Coordinators (CRCs)","CRCs that work on therapeutic clinical trials at Moffitt will have access to the implicit bias educational module and digital tools to monitor and enhance minority recruitment, including the Trial Connect Portal and Recruitment Dashboard.",[27,37,38],"Behavioral: Implicit Bias Training","Behavioral: Recruitment Dashboard",{"label":40,"type":10,"description":41,"interventionNames":42},"Cancer Center Physicians","Physicians at Moffitt will have access to the implicit bias educational module and to digital tools to monitor and enhance minority recruitment, including the Trial Connect Portal, Recruitment Dashboard, Portfolio Profiler, and the Eligibility Criteria Calculator.",[27,37,38,43,44],"Behavioral: Portfolio Profiler","Behavioral: Eligibility Calculator",[46,52,56,60,64,68,72,76,80,84,88],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"BEHAVIORAL","Continuing Medical Education Events (CME)","An engaging 1-hour informational session focusing on topic areas such as implicit bias and emerging evidence from recent cancer clinical trials with CME credit or American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points available.",[23],null,{"type":47,"name":53,"description":54,"armGroupLabels":55,"otherNames":51},"Trial Connect Portal","A digital tool to help facilitate rapid referral of patients to clinical trial opportunities at Moffitt.",[34,40,23],{"type":47,"name":57,"description":58,"armGroupLabels":59,"otherNames":51},"Clinical Trial Newsletters","Electronic\u002Fpaper newsletters to highlight open trials at Moffitt that will be distributed by email\u002Fmail.",[23],{"type":47,"name":61,"description":62,"armGroupLabels":63,"otherNames":51},"Implicit Bias Training","A one-hour educational module will cover information on implicit bias to support the recruitment of diverse patients.",[34,40],{"type":47,"name":65,"description":66,"armGroupLabels":67,"otherNames":51},"Recruitment Dashboard","A dynamic dashboard depicting the number of patients recruited to clinical trials by gender, race, ethnicity, age, cancer type, residence in the catchment area, and other key clinical characteristics.",[34,40],{"type":47,"name":69,"description":70,"armGroupLabels":71,"otherNames":51},"Portfolio Profiler","An interactive dashboard to allow cancer center physicians easily identify gaps in the current clinical trial portfolio that may be contributing to racial\u002Fethnic disparities in trial enrollment.",[40],{"type":47,"name":73,"description":74,"armGroupLabels":75,"otherNames":51},"Eligibility Calculator","A digital calculator that will allow for assessment of the potential impact of clinical trial eligibility criteria (e.g., comorbidities, age, lab values) that may disproportionately exclude patients who are Black and Hispanic prior to submission of clinical trial protocols to the Scientific Review Committee.",[40],{"type":47,"name":77,"description":78,"armGroupLabels":79,"otherNames":51},"Clinical Trial Education Sessions (Community Residents Only)","An engaging 1-hour educational session delivered by a community health educator that includes basic information about clinical trials, their importance, myths, need for diversity in the trials process, and resources for finding more information about clinical trials.",[9],{"type":47,"name":81,"description":82,"armGroupLabels":83,"otherNames":51},"ACT WONDER²S Phone-line\u002FEmail (Community Residents and Moffitt Patients)","A study team member will be available for questions via a dedicated phone-line and email for community residents and Moffitt patients with a return contact within 24-hours.",[9],{"type":47,"name":85,"description":86,"armGroupLabels":87,"otherNames":51},"New Patient Information (Moffitt Patients Only)","Including CHOICES DA, a web-based tool to improve multiple aspects of decision-making related to participation in cancer clinical trials.",[9],{"type":6,"name":89,"description":90,"armGroupLabels":91,"otherNames":51},"No Intervention","Control group with no intervention.",[17,30],[93,97],{"name":94,"affiliation":95,"role":96},"Susan Vadaparampil, PhD","Moffitt Cancer Center","PRINCIPAL_INVESTIGATOR",{"name":98,"affiliation":95,"role":96},"Dana Rollison, PhD",[100,105],{"name":101,"role":102,"phone":103,"phoneExt":51,"email":104},"Rossybelle Amorrortu, MPH","CONTACT","813-745-4007","Rossybelle.Amorrortu@moffitt.org",{"name":106,"role":102,"phone":51,"phoneExt":51,"email":107},"Lindsay Fuzzell, PhD","Lindsay.Fuzzell@moffitt.org",[109],{"facility":95,"status":110,"city":111,"state":112,"zip":113,"country":114,"countryCode":115,"cosmosGeoPoint":116,"geoPoint":121,"contacts":122},"RECRUITING","Tampa","Florida","33612","United States","US",{"type":117,"coordinates":118},"Point",[119,120],-82.45843,27.94752,{"lat":120,"lon":119},[123,124,126,127,128,131,133,135,137,139,141,143],{"name":101,"role":102,"phone":103,"phoneExt":51,"email":104},{"name":106,"role":102,"phone":51,"phoneExt":51,"email":125},"Linsday.Fuzzell@moffitt.org",{"name":94,"role":96,"phone":51,"phoneExt":51,"email":51},{"name":98,"role":96,"phone":51,"phoneExt":51,"email":51},{"name":129,"role":130,"phone":51,"phoneExt":51,"email":51},"Kea Turner, PhD","SUB_INVESTIGATOR",{"name":132,"role":130,"phone":51,"phoneExt":51,"email":51},"Kedar Kirtane, MD",{"name":134,"role":130,"phone":51,"phoneExt":51,"email":51},"Hatem Soliman, MD",{"name":136,"role":130,"phone":51,"phoneExt":51,"email":51},"Margaret Byrne, PhD",{"name":138,"role":130,"phone":51,"phoneExt":51,"email":51},"Cathy Meade, PhD",{"name":140,"role":130,"phone":51,"phoneExt":51,"email":51},"Clement Gwede, PhD",{"name":142,"role":130,"phone":51,"phoneExt":51,"email":51},"Steven Eschrich, PhD",{"name":144,"role":130,"phone":51,"phoneExt":51,"email":51},"Vivien Yin, PhD",{"type":146,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR",[148],{"name":149,"class":150},"National Cancer Institute (NCI)","NIH","100559151","working-through-outreach-navigation-and-digital-enabled-referral-and-recruitment-strategies-act-wonders-100559151",false,"NCT06560398","Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)","ACT WONDER²S","Inclusion Criteria:\n\n* Community residents: Community residents may engage with various intervention components deployed in the intervention priority zones.\n* Community Physicians: may engage with various intervention components deployed in the intervention priority zones if they 1) practice medicine in one of the geographic priority zones.\n* Cancer Center Physicians: may engage with various intervention components if they 1) practice medicine at Moffitt.\n* Clinical Research Coordinators (CRC): may engage with various intervention components if they 1) work as a CRC at Moffitt and 2) coordinate\u002Fpre-screen patients for at least 1 therapeutic clinical trial at Moffitt.\n* Cancer Center Patients: may engage with various intervention components if they have an address that maps to an intervention priority zone and 2) are newly registered patients or new existing patients (NEPs).\n\nExclusion Criteria:\n\n* Community residents, Community Physicians, Cancer Center Physicians, Clinical Research Coordinators, and Moffitt patients who do not meet the inclusion criteria.",true,"ALL","18 Years",{"count":162,"type":163},7649,"ESTIMATED","INTERVENTIONAL",[166],"NA","The purpose of the study is to refine, finalize, implement, and evaluate a multi-level intervention aimed at increasing enrollment of Black and Hispanic patients to National Cancer Institute (NCI)-sponsored therapeutic clinic trials at Moffitt Cancer Center.",[169],"Cancer","2026-03-31",{"date":172,"type":173},"2026-04-01","ACTUAL",{"date":175,"type":173},"2024-09-18",{"date":177,"type":163},"2026-09-01",{"name":5,"class":6},1]